Proshares Ultra Nasdaq Biotech

Gilead Issues $3 Billion Senior Notes for General Corporate Purposes

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Daiwa Securities Downgrades Amgen's Target Price to $390.00

WHO Procurement Mechanism Selects South African Lab to Produce AIDS Generic Drug

Amgen Advances Obesity Drug MariTide to Phase III Trial

Analysts at Cantor Fitzgerald and Bernstein Give Buy Rating to Gilead Sciences

Gilead Sciences released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 6.96 B (forecast USD 6.929 B), actual EPS USD 1.61 (forecast USD 1.5805)

Gilead Sciences Raises 2026 Sales Forecast

Gilead Sciences reports Q1 product sales of $6.946 billion

WealthShield Partners LLC builds new position and increases holdings in Gilead Sciences

Amgen Invests in Expanding Its Research Center to Accelerate Drug Development

Vertex Pharmaceuticals Reports Q1 Revenue Below Expectations, EPS Above Expectations

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

Pinned News

置顶新闻

BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary

PHGE

DFNS

SBIO

LABU

IBBQ

BiomX Inc. reported a net loss of $19.14M for Q1 2026, up from $7.66M in Q1 2025, as it shifts focus from biopharma to defense technology. The company acquired Zorronet and a 60% stake in DFSL, launching a new unit, X Security. Revenue contributions from these acquisitions are expected starting Q2 2026, with active projects underway with major clients.

TradingView

T3 Defense

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Elbit

INBX

Transcenta reported positive interim results from partner Inhibrx’s trial of ozekibart for advanced colorectal cancer, showing a 20% overall response rate and manageable side effects. Inhibrx has also filed for U.S. approval of ozekibart for chondrosarcoma. Transcenta is reviewing its regional plans following these developments and Inhibrx plans to meet the FDA in late 2026 to discuss further trials.

PUBT

Inhibrx Biosciences

TRANSCENTA-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Transcenta partner Inhibrx reports 20% ORR in ozekibart colorectal cancer trial

NBTX

ARKG

Nanobiotix has launched a global follow-on offering aiming to raise approximately EUR 75 million, consisting of a US public offering of ADSs and an international offering of ordinary shares and pre-funded warrants. Jefferies, TD Cowen, and Stifel will serve as global coordinators. The pricing is expected before the US market opens on May 21, 2026, with net proceeds primarily allocated for Nanoprimer and other platforms.

Nanobiotix SA

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

Jefferies Financial

Toronto Dominion Bank

Stifel Financial

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Nanobiotix launches EUR 75 million global follow-on offering of shares, warrants

HOWL

Luke Evnin, a director at Werewolf Therapeutics, sold 171,049 common shares between May 18-20, 2026, at average prices of $0.5, $0.45, and $0.43. Following these transactions, his indirect holdings decreased to 955,447 shares.

Werewolf Therapeutics

Werewolf Therapeutics director Luke Evnin sells USD 76,536 common shares

Dyne Therapeutics has granted inducement equity awards to 17 new hires, including 296,500 stock options priced at the May 20 Nasdaq closing price. The options have a 10-year term and vest over four years, with 25% vesting on the first anniversary. Additionally, 94,100 restricted stock units will vest in four equal annual installments. These awards are part of Dyne's 2024 Inducement Stock Incentive Plan.

Dyne Therapeutics

Dyne Therapeutics grants inducement awards to 17 hires, including 296,500 stock options

TXMD

TherapeuticsMD Inc. (TXMD) shares rose 1.96% to $2.08 on a strong trading day, marking the fourth consecutive day of gains. The NASDAQ Composite Index increased by 1.54%, while the Dow Jones Industrial Average rose 1.31%. TXMD remains 29.49% below its 52-week high of $2.95. In contrast, competitor AbbVie Inc. (ABBV) fell 0.68% to $212.30. Trading volume was below the 50-day average.

MarketWatch Automated

Therapeutics MD

iShares Global Healthcare

NASDAQ Composite Index

Dow Jones Industrial Average

Abbvie

TherapeuticsMD Inc. Stock Outperforms Competitors On Strong Trading Day

OCGN

Ocugen Inc. (OCGN) shares rose 4.62% to $1.36 on Wednesday, outperforming the market as the S&P 500 and Dow Jones also increased. This rise ended a four-day losing streak, although the stock remains 50.09% below its 52-week high of $2.73 reached on March 17. Trading volume was 4.0 million, below the 50-day average of 9.4 million.

Ocugen

S&P 500

Factset Research

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

NVAX

Novavax Inc. (NVAX) shares rose 4.16% to $9.27, outperforming competitors on a positive trading day. The NASDAQ Composite increased by 1.54%, while the Dow Jones rose 1.31%. Despite the gain, NVAX remains 22.56% below its 52-week high of $11.97. Competitors like Johnson & Johnson and Merck saw declines, while Pfizer experienced a slight increase. Trading volume reached 4.9 million, surpassing the 50-day average of 4.3 million.

Novavax

Johnson & Johnson

Pfizer

Merck

Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

CRBP

Corbus Pharmaceuticals Holdings Inc. (CRBP) shares rose 6.34% to $9.73, outperforming competitors on a strong trading day. The NASDAQ Composite Index increased by 1.54%, while the Dow Jones Industrial Average rose 1.31%. Despite the gain, CRBP remains 52.68% below its 52-week high of $20.56. Trading volume reached 289,195, surpassing its 50-day average of 261,108.

Corbus Pharma

Vanda Pharma

Fortress Biotech

Viking Therap

Fortress Biotech Pref Share FBIOP 9.375 15/12/22

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

ASPI

ASP Isotopes has published its latest investor presentation on its website as of May 20, 2026. The presentation is available on the company's homepage.

ASP Isotopes

ASP Isotopes posts latest investor presentation on website

INCY

Incyte Corp. (INCY) shares rose 1.55% to $97.08 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.08%, while the Dow Jones Industrial Average rose 1.31%. Incyte's stock remains 13.55% below its 52-week high of $112.29. Trading volume was 1.1 million, below the 50-day average of 1.5 million.

Incyte

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Neurothera Labs Inc. has adopted a semi-annual financial reporting framework effective immediately, under the CBO 51-933 exemption. This change allows the company to avoid filing interim reports for the first and third quarters, reducing administrative burdens. Neurothera will continue to file annual audited financial statements and six-month interim reports. The company confirms it meets eligibility criteria, including annual revenues under $10 million.

TheNewswire

Proshares UltraShort Nasdaq Biotech

SciSparc

Neurothera Labs Announces Adoption of Semi-Annual Reporting

Proshares Ultra Nasdaq Biotech(BIB.US)